Galunisertib - Eli Lilly and Company
Alternative Names: LY-2157299Latest Information Update: 12 Aug 2024
At a glance
- Originator Eli Lilly and Company
- Developer AstraZeneca; Eli Lilly and Company; National Cancer Institute (USA); University of Oklahoma; Vanderbilt-Ingram Cancer Center; Weill Cornell Medical College
- Class Antineoplastics; Pyrazoles; Pyridines; Pyrroles; Quinolines; Small molecules
- Mechanism of Action Phosphotransferase inhibitors; Transforming growth factor beta1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Breast cancer; Cancer; Colorectal cancer; Glioblastoma; Glioma; Liver cancer; Myelodysplastic syndromes; Non-small cell lung cancer; Pancreatic cancer; Rectal cancer; Sarcoma; Solid tumours; Triple negative breast cancer
Most Recent Events
- 13 Feb 2024 University of Oklahoma and Eli Lilly complete a phase I trial in Sarcoma (Combination therapy, Newly diagnosed, Recurrent) in USA (PO) (NCT03206177)
- 03 Jun 2022 Efficacy and adverse events data from phase-II trial in Rectal cancer presented at the 58th Annual Meeting of the American Society of Clinical Oncology (ASCO-2022)
- 29 May 2020 Efficacy and adverse events data from a phase I trial in Liver cancer presented at the 56th Annual Meeting of the American Society of Clinical Oncology (ASCO-2020)